Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

HIV Vaccines: From Basic Research to Clinical Trials (X7)

Organizer(s): Dennis R. Burton, Alexandra Trkola and David I. Watkins
March 25 - 30, 2007
Whistler Conference Centre (meeting only) · Whistler, British Columbia
Abstract Deadline: November 27, 2006
Late Abstract Deadline: December 27, 2006
Scholarship Deadline: November 27, 2006
Early Registration Deadline: January 25, 2007

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation; Sponsored by Wyeth Vaccines Research

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this educational activity for a maximum of 28-35 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

To receive CME credits, mark the box on the registration form, and pay the additional $50.00.

Joint meeting: Molecular and Cellular Determinants of HIV Pathogenesis (X8)
NOTE: Registration for meeting allows attendance at joint meeting (pending space availability).

This meeting took place in the 2007 season.

Listed below are current meetings that are similar to this meeting in nature/content:

Protection from HIV: Targeted Intervention Strategies (X8)
March 20 - 25, 2011

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
The development of a successful vaccine against HIV-1 faces enormous hurdles. The generation of immunogens able to elicit broadly-reactive neutralizing antibodies in humans remains elusive. The mechanisms responsible for the strong protection seen in macaques vaccinated with attenuated viruses are unknown. Furthermore, we do not fully understand why this virus persists or how some individuals control virus. The nature of transmitted viruses is still unclear. The meeting will focus on recent advances in the understanding of the interplay between the virus and the immune system that are of particular relevance for vaccine design. Leading experts in the field will provide us with insight into key findings in the area of cellular and humoral immunity to HIV, the design of novel immunogens and the mechanism of live attenuated vaccine protection. A strong emphasis of the meeting will also be on recent progress in human vaccine trials.

Objectives
Upon completion of this conference, participants should be able to:

To explain current knowledge regarding structural features of HIV Env glycoproteins, including the structures of highly conserved epitopes for neutralizing antibodies.
To describe the newest information regarding protective humoral and cellular responses against HIV.
To discuss the most recent knowledge regarding transmission of HIV.
To assess current knowledge regarding the development of anti-HIV vaccines.

Sunday, March 25
3:00 - 7:30 PM	Registration	Foyer
6:30 - 7:30 PM	Refreshments	Foyer
7:30 - 9:30 PM	Keynote Session (Joint)	Ballroom B/C
	Richard A. Koup, National Institutes of Health Immunopathogenesis of HIV Infection

	Jonathan W. Yewdell, National Institutes of Health Gained in Translation: Defective Ribosomal Products (DRiPs) as a Principal Source of MHC Class I Peptide Ligands
Monday, March 26
7:00 - 8:00 AM	Breakfast	Foyer, Ballroom A, Lower Level
8:00 - 11:15 AM	Transmission and New Infection (Joint)	Ballroom B/C
	* Julie M. Overbaugh, Fred Hutchinson Cancer Research Center
	Dorothy A. Mbori-Ngacha, University of Nairobi School of Medicine Mother-to-Child Transmission: From Research Policy to Implementation
	Douglas D. Richman, University of California, San Diego HIV Transmission
	Cynthia A. Derdeyn, Emory University Immune Escape in Early Subtype C Infection
	Yang Liu, Monogram Biosciences Short Talk: Neutralization and Envelope Sequence Characteristics of a Subtype B HIV-1 Sexual Transmission Cluster: One Source and Four Recipients
	Guido Silvestri, University of Pennsylvania School of Medicine Understanding the Benign Nature of SIV Infection in Natural Hosts
	Fran Van Heuverswyn, Institute of Research for Development (IRD) Short Talk: SIV Infection in Wild Gorillas and Chimpanzees in Cameroon
9:20 - 9:40 AM	Coffee Break	Grand Foyer
11:15 AM - 1:00 PM	Poster Setup	Grand Foyer/Mountain View/Ballroom A
1:00 - 10:00 PM	Poster Viewing	Grand Foyer/Mountain View/Ballroom A
4:30 - 5:00 PM	Coffee Available	Grand Foyer
5:00 - 7:15 PM	Live Attenuated Vaccines	Ballroom B
	* Ronald C. Desrosiers, New England Primate Research Center Use of gamma-2 Herpesviruses as Vaccine Viruses for AIDS
	Louis J. Picker, Oregon Health & Science University The Cellular Immune Response in Macaques Infected with Attenuated SIV
	Jeffrey D. Lifson, SAIC-Frederick, Inc. Insights into Control of Pathogenic Viral Replication by Pharmacological Modulation of Virus/Host Balance in Primary SIV Infection?
	Marjorie Robert-Guroff, National Cancer Institute, National Institutes of Health Prime/Boost HIV Vaccine Strategies Based on Replication Competent Adenovirus Recombinants
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Grand Foyer/Mountain View/Ballroom A
7:30 - 10:00 PM	Poster Session 1	Grand Foyer/Mountain View/Ballroom A
Tuesday, March 27
7:00 - 8:00 AM	Breakfast	Foyer, Ballroom A, Lower Level
8:00 - 11:00 AM	Immune Responses and HIV Vaccine Development	Ballroom B
	* David I. Watkins, University of Wisconsin-Madison Vaccine-Induced Cellular Immune Responses in Monkeys
	Philip J. Goulder, University of Oxford CD8 T-Cell-Mediated Control of the C Clade HIV Epidemic in Sub-Saharan Africa
	Otto O. Yang, University of California, Los Angeles Interactions of Nef and CTL
	John R. Mascola, NIAID, National Institutes of Health Epitope Specific Neutralizing Antibody Responses
	Galit Alter, Massachusetts General Hospital Short Talk: Significant Inhibition of HIV-1 Replication by KIR3DS1+ NK Cells Derived From KIR3DS1+/HLA-Bw480I+ Individuals
9:20 - 9:40 AM	Coffee Break	Grand Foyer
11:00 AM - 1:00 PM	Poster Setup	Grand Foyer/Mountain View/Ballroom A
1:00 - 10:00 PM	Poster Viewing	Grand Foyer/Mountain View/Ballroom A
2:00 - 4:30 PM	Workshop 2: gp41 as an HIV Vaccine Target	Ballroom B
	Gilad A. Ofek, National Institutes of Health Epitope-Scaffold Immunogens: Design, Characterization, and Molecular Mimicry of the 2F5 Epitope
	Jean-Philippe Julien, University of Toronto Structural Insights into the Mechanism of Neutralization of the nmAb 2F5 Against HIV-1: Conformations of the 2F5 CDR3 Extended Loop and Residues Located at the C-Terminus of the DKW Core
	Michael B. Zwick, The Scripps Research Institute Antibodies Against the N-heptad Repeat Hydrophobic Pocket Region of gp41 are Elicited During Natural Infection and by Immunization But Sterics Can Restrict Neutralization of Primary HIV-1
	Marinieve Montero, CFRI/University of British Columbia Immunogenicity of the Membrane Proximal External Region of HIV-1 gp41 in the Context of the Cell Surface
	Sylvain Fleury, Mymetics Corporation Without Mucosal Adjuvant, Virosomes-gp41 Peptides from the MPR can Elicit Protective Mucosal IgA in Vaccinated Macaques.
	Carl R. Alving, Walter Reed Army Institute of Research Neutralizing Effects on HIV-1 of Murine and Human Monoclonal Antibodies That Bind to Phosphatidylinositol-4-phosphate
	* Jamie K. Scott, Simon Fraser University Reactivity Profiles of HIV-1-Neutralizing MAbs, 2F5 and 4E10, and the Anti-Cardiolipin MAb, CL15
	Xiaoying Shen, Duke University Analysis of a Rare HIV Envelope Sequence that is Highly Sensitive to Broadly Neutralizing Antibodies 2F5 and 4E10
	Christopher J. Richards, National Cancer Institute, National Institutes of Health Activity of an Affordable Fusion Inhibiting Peptide
	* Carol D. Weiss, U.S. Food and Drug Administration Novel Mechanism of Resistance to HIV-1 Peptide Fusion Inhibitors
4:30 - 5:00 PM	Coffee Available	Grand Foyer
5:00 - 7:00 PM	HIV Vaccine Program Updates	Ballroom B
	* Douglas D. Richman, University of California, San Diego
	Barton F. Haynes, Duke University Medical Center Update On CHAVI B Cell and Transmitted Virus Discovery Programs
	Wayne C. Koff, International AIDS Vaccine Initiative IAVI R&D Program Update: Fostering Innovation in AIDS Vaccine Discovery and Development
	Gary J. Nabel, National Institutes of Health Pushing the Envelope of HIV Vaccines: From Basic Research to Clinical Trials

7:00 - 8:00 PM	Social Hour w/ Lite Bites	Grand Foyer/Mountain View/Ballroom A
7:30 - 10:00 PM	Poster Session 2	Grand Foyer/Mountain View/Ballroom A
Wednesday, March 28
7:00 - 8:00 AM	Breakfast	Foyer, Ballroom A, Lower Level
8:00 - 11:00 AM	Structures (Joint)	Ballroom B/C
	* Dennis R. Burton, The Scripps Research Institute
	Peter D. Kwong, Vaccine Research Center, National Institutes of Health A Structural Approach to Vaccine Design
	Stephen C. Harrison, Harvard Medical School HIV and SIV Env Glycoproteins
	Ian A. Wilson, The Scripps Research Institute HIV Neutralizing Antibody Structures
	Wesley I. Sundquist, University of Utah School of Medicine Mechansims of HIV Budding
	Harold C. Smith, University of Rochester Short Talk: Nanostructures of APOBEC3G Support a Hierarchical Assembly Model of High Molecular Mass Ribonucleoprotein Particles from Dimeric Subunits
9:20 - 9:40 AM	Coffee Break	Grand Foyer
11:00 AM - 1:00 PM	Poster Setup	Grand Foyer/Mountain View/Ballroom A
1:00 - 10:00 PM	Poster Viewing	Grand Foyer/Mountain View/Ballroom A
4:30 - 5:00 PM	Coffee Available	Grand Foyer
5:00 - 7:00 PM	Relevant Lessons from Other Systems	Ballroom B

	Kasper Hoebe, The Scripps Research Institute The Innate-Adaptive Connection: TLRs and Beyond


	Annette Oxenius, Institute for Microbiology, ETH Zürich CD8+ T Cell Dysfunction during Chronic Viral Infections


	Richard T. Wyatt, National Institutes of Health HIV-1 gp120 Structure-based Immunogen Design

	David A. Price, NIAID, National Institutes of Health Short Talk: Evolution of Cytomegalovirus-Specific CD4+ T Cell Clonotypes in vivo: Vaccine Design Informed by Successful Immune Responses
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Grand Foyer/Mountain View/Ballroom A
7:30 - 10:00 PM	Poster Session 3	Grand Foyer/Mountain View/Ballroom A
Thursday, March 29
7:00 - 8:00 AM	Breakfast	Foyer, Ballroom A, Lower Level
8:00 - 11:00 AM	Mechanisms of Viral Persistence and Immune Avoidance (Joint)	Ballroom B/C
	Alan N. Engelman, Dana Farber Cancer Institute Host Factors and HIV-1 Integration
	Charles R.M. Bangham, Imperial College School of Medicine Efficiency of the Anti-Viral CTL Response: HTLV-1
	Alexandra Trkola, Institute of Medical Viroloy Prospects of Humoral Immunity to HIV-1
	Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard Elite Control of HIV: Implications for Vaccine Design
	Jason M. Brenchley, NIAID, National Institutes of Health Short Talk: Microbial Translocation is a Cause of Systemic Immune Activation in Chronic HIV Infection
9:20 - 9:40 AM	Coffee Break	Grand Foyer
11:00 AM - 12:00 PM	Poster Setup	Grand Foyer/Mountain View/Ballroom A
11:00 AM - 12:00 PM	Lunch	Grand Foyer/Mountain View/Sky Ballroom A
12:00 - 4:30 PM	Poster Session 4	Grand Foyer/Mountain View/Ballroom A
2:00 - 4:30 PM	Workshop 4: CTL Function, Dysfunction and Escape	Ballroom B
	* Marcus Altfeld, Massachusetts General Hospital

	* Otto O. Yang, University of California, Los Angeles
	Tedi E. Asher, NIAID, National Institutes of Health Clonal Correlates of Vaccine-Induced Immune Protection Against SIV in Rhesus Macaques
	Sylvie Le Gall, Massachusetts General Hospital, Harvard Medical School Intracellular Epitope Stability is Defined by Specific Residues and Correlates With HIV Epitope Hierarchy
	Emma L. Turnbull, Jenner Institute, University of Oxford Mutational Escape, Rather than Reduced Avidity of Epitope-Specific T Cell Responses, may be More Relevant for Impairment of the HIV-Specific CD8+ T Cell Response During Early HIV-1 Infection
	Jonah B. Sacha, University of Wisconsin-Madison Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression
	Hendrik Streeck, Massachusetts General Hospital, Harvard Medical School Immunodomination by HLA-B27/-B57 Results in a Substantial Abrogation of Alternate HLA-Restricted HIV-Specific Responses in Primary HIV-1 Infection
	Hayley Crawford, Oxford University Compensatory Mutation Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant HLA-B5703-Restricted Gag Epitope in Chronic HIV Infection*

	Nicole Frahm, Fred Hutchinson Cancer Research Center Preferential Targeting of HIV-Gag Epitopes in Elite Controllers
	Hanneke Schuitemaker, Academic Medical Center at the University of Amsterdam Differential Clinical Course in HLA B57+ Long-Term Nonprogressors and Progressors Does not Relate to Frequencies of Gag Specific Cytotoxic T Lymphocytes or Sequence Dynamics in Gag CTL Epitopes but to HIV-1 Replicative Capacity
	Stephen A. Migueles, National Institutes of Health Diminished Proliferative Capacity of HIV-Specific CD8+ T Cells is not Restored by Antiretroviral Therapy or Exogenous IL-2
	Teresa Lea Mattila, University of Minnesota In Situ Analysis of Virus-Specific CD8+ T Cells
4:30 - 5:00 PM	Coffee Available	Grand Foyer
5:00 - 7:00 PM	Novel Immunogens	Ballroom B
	* Ian A. Wilson, The Scripps Research Institute

	Hiroyuki Yamamoto, Institute of Medical Science, The University of Tokyo SIV Control by Post-Infection Passive Immunization of Neutralizing Antibodies
	Ping Zhu, Florida State University 3D HIV-1 Envelope Spike Model as Revealed by Cryoelectron Tomography
	Giulia Zanetti, Wellcome Trust Centre, University of Oxford Cryo-Electron Tomography of SIV Envelope Complex in situ
	Sriram Subramaniam, National Institutes of Health Electron Tomography of Immunodeficiency Viruses and Structural Mechanisms of Cellular Entry
	Quentin J. Sattentau, Sir William Dunn School of Pathology Increasing HIV-1 Env Immunogenicity by Modulation of Intrinsic and Extrinsic Factors
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Grand Foyer/Mountain View/Ballroom A
8:00 - 11:00 PM	Entertainment	Grand Foyer/Mountain View/Ballroom A
Friday, March 30
	Departure

*Session Chair †Speaker invited, not yet responded.